Literature DB >> 10216129

Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.

S Radaeva1, A Ferreira-Gonzalez, A E Sirica.   

Abstract

Based on limited but compelling immunohistochemical data demonstrating individual overexpression of the tyrosine kinase growth factor receptors, c-erbB-2 and c-met, in significant percentages of human cholangiocarcinoma (ChC), we investigated if combined overexpression of both c-neu, the rat homologue of c-erbB-2, and c-met, the receptor for hepatocyte growth factor/scatter factor (HGF/SF), might represent a characteristic, early event associated with furan-induced cholangiocarcinogenesis in rat liver. Specifically, through the use of immunohistochemistry, in situ hybridization (ISH), and Western and Northern blotting, we found that both c-neu and c-met are prominently overexpressed in intestinal metaplastic lesions in early putative precancerous cholangiofibrotic tissue formed in the livers of rats after 6 weeks of furan treatment when compared with normal and hyperplastic intrahepatic biliary epithelia. We further demonstrated that c-neu and c-met are concordantly overexpressed in neoplastic glandular epithelia in later-developed primary "intestinal-type" of ChC formed in the livers of furan-treated rats, as well as in subsequently derived transplantable mucin-producing tumors. Overexpression of c-neu and c-met correlated with increased proliferating cell nuclear antigen (PCNA)-labeling indices, which were determined to be three to four times higher in intestinal metaplastic glands in precancerous cholangiofibrotic tissue and in neoplastic glands in the primary "intestinal type" of ChC than in hyperplastic bile ductular structures within either cholangiofibrotic or bile duct-ligated (BDL) livers. The c-neu and c-met receptor proteins overexpressed in different in vivo passages of a transplantable ChC each contained immunoreactive phosphotyrosines, indicating an activated state. However, we did not detect evidence of either gene amplification of c-neu or c-met or of a common transmembrane-activating mutation in c-neu expressed in transplantable ChC. Our findings indicate that altered expression of c-neu and c-met occurs relatively early in the process of furan-induced cholangiocarcinogenesis in rat liver and may play a potentially important role in its pathogenesis. They further indicate a common alteration in tyrosine kinase growth factor receptor expression linking early putative precancerous intestinal metaplastic lesions in liver to later-developed mucin-producing biliary cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216129     DOI: 10.1002/hep.510290524

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

1.  Liver damage using suicide genes. A model for oval cell activation.

Authors:  M Bustos; B Sangro; P Alzuguren; A G Gil; J Ruiz; N Beraza; C Qian; A Garcia-Pardo; J Prieto
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 2.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 3.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 4.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

5.  Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA.

Authors:  Chun-Nan Yeh; Kun-Ju Lin; Tsung-Wen Chen; Ren-Ching Wu; Lee-Cheng Tsao; Ying-Tzu Chen; Wen-Hui Weng; Miin-Fu Chen
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

6.  Characterization of a new rat cell line established from 2'AAF-induced combined hepatocellular cholangiocellular carcinoma.

Authors:  R Gil-Benso; A Martinez-Lorente; A Pellin-Perez; S Navarro-Fos; M A Gregori-Romero; C Carda; R Callaghan; A Peydro-Olaya; A Llombart-Bosch
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-01       Impact factor: 2.416

7.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

Review 8.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

9.  Leptin enhances cholangiocarcinoma cell growth.

Authors:  Giammarco Fava; Gianfranco Alpini; Chiara Rychlicki; Stefania Saccomanno; Sharon DeMorrow; Luciano Trozzi; Cinzia Candelaresi; Julie Venter; Antonio Di Sario; Marco Marzioni; Italo Bearzi; Shannon Glaser; Domenico Alvaro; Luca Marucci; Heather Francis; Gianluca Svegliati-Baroni; Antonio Benedetti
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

10.  A Case Report of Intraductal Papillary-Mucinous Neoplasm of the Pancreas Showing Morphologic Transformation during Followup Periods.

Authors:  Yuichi Sanada; Shinji Osada; Yoshihiro Tanaka; Yasuharu Tokuyama; Kazuhiro Yoshida
Journal:  J Oncol       Date:  2009-10-15       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.